Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Open Access
- 7 February 2022
- book chapter
- Published by Springer Nature
- p. 141-145
Abstract
A common and challenging side effect associated with CAR-T cell therapy is immune cell-associated neurotoxicity syndrome (ICANS), which occurs in 20–60% of patients, of whom 12–30% have severe (≥ grade 3) symptoms.Keywords
Funding Information
- European Society for Blood and Marrow Transplantation
- The European Hematology Association
This publication has 3 references indexed in Scilit:
- Neurological updates: neurological complications of CAR-T therapyJournal of Neurology, 2020
- Neurotoxicity—CAR T-cell therapy: what the neurologist needs to knowPractical Neurology, 2020
- Neurological toxicities associated with chimeric antigen receptor T-cell therapyBrain, 2019